EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 579 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR For Cancer Screening, COVID-19 Pandemic Creates Obstacles, Opportunities March 10, 2021 Ovarian, bowel and non-Hodgkin’s lymphoma treatments approved for NHS use in... December 16, 2021 Adding Atezolizumab to Chemotherapy Does Not Improve Outcomes in Patients Who... June 4, 2024 EMA Recommends Extension of Indications for Pirtobrutinib April 24, 2025 Load more HOT NEWS Teen With Cancer On Dream Trip To NASA Gets Surprise Call... What could DeepMind ‘solving’ the protein folding problem mean for cancer... This Common Antibiotic May Help Support Immune System in Cancer Patients... Women Who Consume Cows’ Milk Increase Their Risk Of Breast Cancer...
